RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GENOVA C
Collezione AOU Novara

Items : 20

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1?50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. in Journal for immunotherapy of cancer / J Immunother Cancer. 2025 Feb 4;13(2):e010674. doi: 10.1136/jitc-2024-010674.

2025
AOU San Luigi di Orbassano
AOU Novara

Wakelee H; Garassino M; Peters S; Takada K; Naqash AR; Torri V; Hejleh TA; Ferrara R; Aerts JGJV; Aboubakar Nana F; Dingemans AM; Biello F; Rogado J; Moliner L; Beninato T; Lo Russo G; Servetto A; Mezquita L; Gorría T; Minuti G; Bennati C; Tonini G; Cortinovis DL; Agustoni F; Majem M; Baena J; Macerelli M; Monnet I; O'Reilly D; et alii...

APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research. in Clinical lung cancer / Clin Lung Cancer. 2024 Mar;25(2):190-195. doi: 10.1016/j.cllc.2023.12.012. Epub 2023 Dec 22.

2024
AOU Novara

Beninato T; Manglaviti S; Occhipinti M; Vigorito R; Greco GF; Ruggirello M; Calareso G; Mazzoni F; Sangaletti S; Agnelli L; Lorenzini D; Auletta P; Trovò F; Grisanti S; Vita E; Spinelli G; Tartarone A; Aieta M; Buzzacchino F; Lugini A; Pisconti S; Bareggi C; Verderame F; Emili R; Macerelli M; Pecci F; Cantini L; Berardi R; Bertolini F; et alii...

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab. in Clinical and experimental medicine / Clin Exp Med. 2024 Aug 6;24(1):182. doi: 10.1007/s10238-024-01427-8.

2024
AOU San Luigi di Orbassano
AOU Novara

Gil-Bazo I; Baraibar I; Biello F; Rivoltini L; Chiari R; Baglivo S; Metro G; Passiglia F; Barletta G; Ludovini V; Rijavec E; Alama A; Dellepiane C; Dal Bello MG; Zullo L; Tagliamento M; Longo L; Vanni I; Rossi G; Ostano P; Santamaria S; Guana F; Chiorino G; Marconi S; Genova C; Novello S; Grossi F; Coco S;

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.

2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Porzio G; Tiseo M; Russano M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Metro G; Migliorino MR; Passiglia F; Ricciardi S; Zoratto F; Pecci F; Di Marino P; Mansueto G; De Tursi M; Tuzi A; Gori S; Della Gravara L; Macerelli M; Rastelli F; Chiari R; Gelibter A; Marchetti P; Antonuzzo L; Mazzoni F; et alii...

Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ?50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. in Thoracic cancer / Thorac Cancer. 2022 Feb;13(3):483-488. doi: 10.1111/1759-7714.14256. Epub 2021 Dec 22.

2022
AOU Novara

Banna GL; Tiseo M; Cortinovis DL; Facchinetti F; Aerts JGJV; Baldessari C; Giusti R; Bria E; Grossi F; Berardi R; Morabito A; Catino A; Genova C; Mazzoni F; Gelibter A; Rastelli F; Macerelli M; Chiari R; Gori S; Mansueto G; Citarella F; Cantini L; Rijavec E; Bertolini F; Cappuzzo F; De Toma A; Friedlaender A; Metro G; Pensieri MV; et alii...

Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review). in Molecular and clinical oncology / Mol Clin Oncol. 2022 Apr;16(4):89. doi: 10.3892/mco.2022.2522. Epub 2022 Feb 22.

2022
AOU Novara

Rijavec E; Biello F; Barletta G; Dellepiane C; Genova C;

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib. in Clinical pharmacology : advances and applications / Clin Pharmacol. 2022 Jan 20;14:1-9. doi: 10.2147/CPAA.S284850. eCollection 2022.

2022
AOU Novara

Rijavec E; Biello F; Indini A; Grossi F; Genova C;

Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer. in Expert review of respiratory medicine / Expert Rev Respir Med. 2021 Nov;15(11):1427-1435. doi: 10.1080/17476348.2021.1987887. Epub 2021 Oct

2021
AOU Novara

Rijavec E; Genova C; Biello F; Rossi G; Indini A; Grossi F;

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Addeo A; Friedlaender A; Banna GL; Di Maio M; Spinelli GP; Russo A; Adamo V; De Filippis M; Metro G; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Buti S; Minuti G; Nigro O; Cantini L; Bracarda S; Citarella F; Russano M; Filetti M; Zoratto F; Gori S; De Tursi M; Mansueto G; Rocco D; et alii...

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. in Cancers / Cancers (Basel). 2021 Jun 22;13(13):3117. doi: 10.3390/cancers13133117.

2021
AOU Novara

Bauckneht M; Genova C; Rossi G; Rijavec E; Dal Bello MG; Ferrarazzo G; Tagliamento M; Donegani MI; Biello F; Chiola S; Zullo L; Raffa S; Lanfranchi F; Cittadini G; Marini C; Lopci E; Sambuceti G; Grossi F; Morbelli S;

Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer. in Clinical breast cancer / Clin Breast Cancer. 2021 Jun;21(3):218-230.e6. doi: 10.1016/j.clbc.2020.09.001. Epub 2020 Sep 6.

2021
AOU Novara

Grossi F; Ballestrero A; Longo L; Burrafato G; Carli F; Cavalieri Z; Sini C; Barletta G; Biello F; Rijavec E; Bonfiglio S; Alama A; Salvi S; Dal Bello MG; Genova C; Vanni I; Fontana V; Mora M; Boccardo S; Coco S;

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cortellini A; Mazzaschi G; Tiseo M; Pinato DJ; Carmisciano L; Ficorella C; Porzio G; Cannita K; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Adamo V; Russo A; Olmetto E; Metro G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Minuti G; Tuzi A; Bisonni R; Follador A; Gelibter A; Siringo M; Signorelli D; De Toma A; Garassino MC; et alii...

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. in Journal for immunotherapy of cancer / J Immunother Cancer. 2021 Apr;9(4):e002421. doi: 10.1136/jitc-2021-002421.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Porzio G; Cannita K; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Russo A; Adamo V; Metro G; Bironzo P; Passiglia F; Ricciardi S; Migliorino MR; Landi L; Minuti G; Tuzi A; Bordi P; Russano M; Cantini L; Santini D; Citarella F; Zoratto F; Filetti M; Mansueto G; Di Marino P; Grassadonia A; Inno A; et alii...

Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico / Clin Transl Oncol. 2020 Sep;22(9):1603-1610. doi: 10.1007/s12094-020-02305-x. Epub 2020 Feb 11.

2020
AOU Novara

Coco S; Spallarossa P; Alama A; Tagliamento M; Biello F; Rossi G; Dal Bello MG; Rijavec E; Ferrara D; Ansaldo AM; Elia E; Bardi N; Minetti S; Vecchié A; Carbone F; Grossi F; Bonaventura A; Dallegri F; Genova C; Montecucco F;

Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. in Expert review of respiratory medicine / Expert Rev Respir Med. 2020 Apr;14(4):367-383. doi: 10.1080/17476348.2020.1714441. Epub 2020 Jan 17.

2020
AOU Novara

Genova C; Rossi G; Tagliamento M; Rijavec E; Biello F; Cerbone L; Zullo L; Grossi F;

Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. in Journal of clinical medicine / J Clin Med. 2019 Oct 1;8(10):1566. doi: 10.3390/jcm8101566.

2019
AOU Novara

Genova C; Boccardo S; Mora M; Rijavec E; Biello F; Rossi G; Tagliamento M; Dal Bello MG; Coco S; Alama A; Vanni I; Barletta G; Bianchi R; Maggioni C; Bruzzi P; Grossi F;

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. in Clinical & experimental metastasis / Clin Exp Metastasis. 2019 Oct;36(5):449-456. doi: 10.1007/s10585-019-09984-z. Epub 2019 Aug 2.

2019
AOU Novara

Genova C; Dallegri F; Coco S; Spallarossa P; Biello F; Rossi G; Alama A; Tagliamento M; Dal Bello MG; Rijavec E; Ferrara D; Ansaldo AM; Elia E; Bardi N; Minetti S; Vecchié A; Bonaventura A; Grossi F; Carbone F; Montecucco F;

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. in Journal of clinical medicine / J Clin Med. 2019 Jul 10;8(7):1011. doi: 10.3390/jcm8071011.

2019
AOU Novara

Cavalieri Z; Longo L; Biello F; Rijavec E; Boccardo S; Rosa A; Giovanna Dal Bello M; Tagliamento M; Fontana V; Rossi G; Genova C; Coco S; Alama A; Bruzzo C; Grossi F;

Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. in Immunotherapy / Immunotherapy. 2019 Jul;11(10):873-879. doi: 10.2217/imt-2019-0025. Epub 2019 Jun 3.

2019
AOU Novara

Rossi G; Rijavec E; Genova C; Paolino S; Grossi F; Tagliamento M; Biello F; De Maria A;

Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2019 Aug;68(8):1351-1358. doi: 10.1007/s00262-019-02367-z. Epub 2019 Jul

2019
AOU Novara

Dallegri F; Coco S; Spallarossa P; Alama A; Tagliamento M; Biello F; Rossi G; Dal Bello MG; Rijavec E; Ferrara D; Ansaldo AM; Elia E; Bardi N; Minetti S; Vecchié A; Carbone F; Grossi F; Bonaventura A; Genova C; Montecucco F;